Fexofenadine transport in Caco-2 cells: Inhibition with verapamil and ritonavir

被引:82
作者
Perloff, MD
von Moltke, LL
Greenblatt, DJ
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Tufts Univ New England Med Ctr, Div Clin Pharmacol, Boston, MA USA
关键词
D O I
10.1177/009127002762491370
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study investigated fexofenadine (FXD) transport and the inhibition of FXD transport in Caco-2 cell monolayer transwells, using rhodamine 123 (1311123) transport as a positive control. FXD transport from the basolateral (B) to apical (A) compartment was fivefold higher than A to B transport. FXD transport was linear with respect to time (up to 270 min) and concentration (up to 300 lam). Similar results were seen with the positive control RH123, Ritonavir (100 W) and verapamil (100 pm) reduced transport of FXD and RH123 by more than 80%, whereas transport was not inhibited by 100 m indomethacin or 2 mM probenecid. This suggests pre-dominantly P-glycoprotein (P-gp)-mediated transport as opposed to transport by multidrug resistance protein. In concentration-response experiments, FXD transport was inhibited by verapamil and ritonavir with IC50 values of 6.5 mum and 5.4 mum, respectively. Results from this in vitro study demonstrate differential transport of FXD across Caco-2 cell monolayers and inhibition of FXD transport by established P-gp inhibitors, The findings support the use of FXD as an index or probe compound to reflect P-gp activity in vivo. (C) 2002 the American College of Clinical Pharmacology.
引用
收藏
页码:1269 / 1274
页数:6
相关论文
共 37 条
[1]   Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[2]   The multidrug resistance protein family [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1461 (02) :347-357
[3]  
Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866
[4]   Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein [J].
Draper, MP ;
Martell, RL ;
Levy, SB .
BRITISH JOURNAL OF CANCER, 1997, 75 (06) :810-815
[5]   Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine [J].
Dresser, GK ;
Bailey, DG ;
Leake, BF ;
Schwarz, UI ;
Dawson, PA ;
Freeman, DJ ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :11-20
[6]   A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: A survival molecule [J].
Gupta, S ;
Aggarwal, S ;
Nakamura, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1998, 18 (04) :256-263
[7]   The effect of rifampin administration on the disposition of fexofenadine [J].
Hamman, MA ;
Bruce, MA ;
Haehner-Daniels, BD ;
Hall, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :114-121
[8]   Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells [J].
Han, HY ;
Secrest, DT ;
Mark, KS ;
Carney, D ;
Brandquist, C ;
Elmquist, WF ;
Miller, DW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 243 (03) :816-820
[9]   Differential pharmacokinetics of digoxin in elderly patients [J].
Hanratty, CG ;
McGlinchey, P ;
Johnston, GD ;
Passmore, AP .
DRUGS & AGING, 2000, 17 (05) :353-362
[10]  
Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO